New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes

Not every diabetes drug needs to be injected. Some kinds are oral and have to be taken by mouth. This talks about a new one which shows promise. Many people around the world have diabetes so this is good news. Many find that the dugs out there don’t work for them so they need to try something else.

Key Takeaways:

  • Sotagliflozin is a drug in phase 3 of testing trials shown to improve glucose control without weight gain.
  • Sotagliflozin also improved hemoglobin AC1 levels.
  • Sotagliflozin could be the first oral drug to help type 1 diabetes and reduce its long term effects.

“Sotagliflozin has shown promise in improving glucose control without any increase in severe hypoglycemia or diabetic ketoacidosis compared to insulin alone.”